Az ESC/EAS 2019. évi lipidajánlása, az LDL-koleszterin-célérték elérésének lehetőségei szívinfarktuson átesett, igen nagy kockázatú betegekben

The new dyslipidaemia guideline of the European Society of Cardiology and European Atherosclerosis Society was published on autumn of 2019. Its novelty was that based on the studies of the latest 3 years the LDL-cholesterol target level had been decreased. Being aware of the present daily practice for the attainment of the new goals more attention has to be paid by the doctors and would require a better adherence from patients. It has to be underlined that the achievement of 1.4 mmol/l LDL-cholesterol level or that of 1.0 mmol/l in the case of recurrent cardiovascular event within 2 years is a great challenge for the statin and combined statin+ezetimibe therapy as well. Beside the more frequent administration of the ezetimibe the use of PCSK9-inhibitors would be needed. These statements are highly valid for